comparemela.com

Latest Breaking News On - Company mechanism of action - Page 1 : comparemela.com

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering

Julian kenyonJames nathanielszKlaus kutzCompany mechanism of actionDrug administrationPropanc biopharma incPropanc biopharmaChief scientific officerActing chief medicalRalf brandt phdScientific advisory board memberChief executive officerExecutive chairmanChief financialDrug designationLooking statements

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

PRP Dosing & Method to Treat Cancer Stem Cells Patents Validated in Countries Across Europe Resulting in Growing IP Portfolio of 87 patents

United statesJames nathanielszCanadian intellectual property officeCompany mechanism of actionEuropean federation of pharmaceutical industriesPropanc biopharma incTreat cancer stem cells patents validatedCountries across europe resultingPropanc biopharmaCanadian intellectual propertyNorth americaMiddle eastEuropean federationPharmaceutical industriesChief executivePrivate securities litigation reform act

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

Propanc Biopharma, Inc. ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company's.

United statesJames nathanielszFoundation patentPropanc biopharma incEuropean federation of pharmaceutical industriesProduct serviceCompany mechanism of actionCanadian intellectual property officeBiopharma receives certificateCanadian intellectual propertyNorth americaMiddle eastEuropean federationPharmaceutical industriesChief executivePropanc biopharma

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities

MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering

James nathanielszCompany mechanism of actionPropanc biopharma incPropanc biopharmaChief executivePrivate securities litigation reform actPress release

Propanc Biopharma s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP

MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering

Noord hollandJames nathanielszPropanc biopharmaToledo cutillasElisa giovanettiJulian kenyonUmc university medical centersCompany mechanism of actionCancer center amsterdamDrug administrationMolecular oncology laboratoryPropanc biopharma incUniversity medical centersCancer centerProfessor elisa giovanettiProfessor giovanetti

vimarsana © 2020. All Rights Reserved.